Skip to main content

Tafinlar Receives Breakthrough Therapy Designation for Lung Cancer

February 2014 Vol 7, No 1, Special Issue ASH 2013 Payers' Perspectives in Oncology - FDA Approvals

A few days after the approval of the combination of the 2 melanoma drugs, the FDA approved dabrafenib (Tafinlar) as a breakthrough therapy designation for lung cancer based on interim results from an ongoing phase 2 clinical trial. (January 13, 2014)

Related Items
FDA Grants Approval to Encorafenib for BRAF V600E–Mutated Metastatic Colorectal Cancer
Web Exclusives published on May 21, 2026 in FDA Approvals
FDA Approves Teclistamab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Web Exclusives published on May 12, 2026 in FDA Approvals
FDA Approves Darzalex Faspro-VRd Combination for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant
Web Exclusives published on April 13, 2026 in FDA Approvals
New Treatment Option for Platinum-Resistant Ovarian Cancer Patients
Web Exclusives published on April 7, 2026 in FDA Approvals
FDA Approves Optune Pax: A Breakthrough Treatment for Locally Advanced Pancreatic Cancer
Web Exclusives published on March 4, 2026 in FDA Approvals
Last modified: August 30, 2021